Boehringer Ingelheim to cash out Hikma stake; Breast cancer biotech sets terms for IPO
→ Boehringer Ingelheim is offloading a major chunk of its holding in Hikma, proposing to sell 28 million out of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
